0001567619-22-018291.txt : 20221005
0001567619-22-018291.hdr.sgml : 20221005
20221005214619
ACCESSION NUMBER: 0001567619-22-018291
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221003
FILED AS OF DATE: 20221005
DATE AS OF CHANGE: 20221005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ekman Lars
CENTRAL INDEX KEY: 0001376117
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35676
FILM NUMBER: 221296980
MAIL ADDRESS:
STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC.
STREET 2: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROTHENA CORP PUBLIC LTD CO
CENTRAL INDEX KEY: 0001559053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C
STREET 2: GRAND CANAL DOCKLANDS
CITY: DUBLIN 2
STATE: L2
ZIP: D02 VK60
BUSINESS PHONE: 011-353-1-236-2500
MAIL ADDRESS:
STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C
STREET 2: GRAND CANAL DOCKLANDS
CITY: DUBLIN 2
STATE: L2
ZIP: D02 VK60
FORMER COMPANY:
FORMER CONFORMED NAME: Prothena Corp plc
DATE OF NAME CHANGE: 20121102
FORMER COMPANY:
FORMER CONFORMED NAME: Neotope Corp Ltd
DATE OF NAME CHANGE: 20120926
4
1
doc1.xml
FORM 4
X0306
4
2022-10-03
0
0001559053
PROTHENA CORP PUBLIC LTD CO
PRTA
0001376117
Ekman Lars
C/O PROTHENA BIOSCIENCES INC
331 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
1
0
0
1
Chair of the Board
Ordinary Shares, par value $0.01 per share
2022-10-03
4
M
0
15833
6.41
A
16076
D
Ordinary Shares, par value $0.01 per share
2022-10-03
4
S
0
3508
60.3204
D
12568
D
Ordinary Shares, par value $0.01 per share
2022-10-03
4
S
0
4277
61.0726
D
8291
D
Ordinary Shares, par value $0.01 per share
2022-10-03
4
S
0
6355
62.1050
D
1936
D
Ordinary Shares, par value $0.01 per share
2022-10-03
4
S
0
1693
62.9609
D
243
D
Stock Option (right to buy)
6.41
2022-10-03
4
M
0
15833
0
D
2023-01-29
Ordinary Shares
15833
47501
D
The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The transaction was executed in multiple trades in prices ranging from $59.60 to $60.59, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 5 of this Form 4.
The transaction was executed in multiple trades in prices ranging from $60.60 to $61.59, inclusive.
The transaction was executed in multiple trades in prices ranging from $61.61 to $62.47, inclusive.
The transaction was executed in multiple trades in prices ranging from $62.66 to $63.47, inclusive.
The option was granted on January 29, 2013, and all shares subject to the option were fully vested and exercisable January 29, 2014. The option will expire in approximately four months and be forfeited to the extent it is not exercised on or prior to January 29, 2023.
/s/ Michael J. Malecek, as attorney-in-fact for Lars G. Ekman
2022-10-05